Loading...
A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease
BACKGROUND: Ustekinumab was approved for moderate and severe Crohn’s disease (CD) in 2016, but little is known about long-term outcomes. METHODS: A retrospective study evaluated all patients with CD treated with ustekinumab, including patients with reinduction. C-reactive protein (CRP), Harvey-Brads...
Na minha lista:
| Udgivet i: | Crohns Colitis 360 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7067228/ https://ncbi.nlm.nih.gov/pubmed/32201860 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/crocol/otaa013 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|